A new clinical trial involving elamipretide was registered on November 10, 2026. The study, titled "Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Subcutaneous Injections of Elamipretide in Pediatric Subjects With Barth Syndrome," is listed under identifier NCT07927972.
The trial is designated as Phase 1 and is intended to assess pharmacokinetics, safety, and tolerability of subcutaneous elamipretide injections in pediatric subjects with Barth syndrome. According to the registration, the study status is currently "not yet recruiting."
No results, efficacy data, or safety findings have been reported as part of this registration. The listing reflects only the planned design and objectives of the study at this stage.
Elamipretide is currently an approved compound, and this trial represents an additional investigation into its use in a pediatric population with Barth syndrome. Further updates on recruitment status or study progress would be expected as the trial moves forward.
Readers interested in background on this compound can consult the elamipretide overview for additional context.